Please login to the form below

Not currently logged in


The Association of the British Pharmaceutical Industry has announced the launch of a new project in Nottingham to improve the treatment of chronic obstructive pulmonary disease
The Association of the British Pharmaceutical Industry (ABPI) has announced the launch of a new project in Nottingham to improve the treatment of chronic obstructive pulmonary disease (COPD).

Industry and Nottingham NHS Focus on Reducing COPD Exacerbations (INFORCE), is aimed at alleviating the burden on the health service created by the disease. It is a collaborative effort between Nottingham Primary Care Trust, Nottingham University Hospitals NHS Trust and five pharmaceutical companies operating under the banner of the ABPI NHS Outreach Programme.

"We all have a shared interest in improving people's health and reducing their need for hospital treatment," said Jan Balmer, regional facilitator for the ABPI. "The pharmaceutical industry is committed to working with the NHS throughout the UK to identify and develop similar opportunities where we can benefit patients by sharing our skills, experience and resources."

COPD affects approximately 3.7 million people in the UK and claims 140 lives every year in Nottingham alone. Although there are about 1,000 hospital admissions in the city per year, some of these are for repeat treatments.

It is hoped that INFORCE will reduce the number of people being admitted to hospital with COPD, the generic name for conditions, such as emphysema and chronic asthma, which cause obstruction of the airways.

"This is an excellent scheme which cuts across organisational boundaries to provide better care for patients," said Dr Johnathan Corne, consultant physician at Nottingham University Hospitals. "I am confident the outcomes of this scheme will help us to improve care of people with COPD and reduce the number of unnecessary admissions to hospital."

This is the second joint scheme the ABPI has embarked on in Nottingham, the first being Happy Hearts, a cardiovascular disease management project.

29th May 2008


Featured jobs

Subscribe to our email news alerts


Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...